Piper Sandler upgraded MetLife and raised its price target, increasing analyst support and potential investor interest; the stock closed at $96.64 versus the $110 target.
The Piper Sandler upgrade increases analyst backing and raises the stock's headline target. That stronger analyst stance tends to raise investor interest in MetLife shares and in expectations for its business.
Northcoast Research upgraded Brinker to Buy and set a $275 target, which raises analyst backing and may increase attention; the shares closed at $200.30.
Keybanc upgraded Plexus to Overweight and set a $300 target, strengthening analyst support and investor interest; Plexus closed at $252.36 on Monday.
Morgan Stanley upgraded West Pharmaceutical to Overweight and raised its price target to $400, which boosts analyst backing; shares closed at $361.78 on Monday.
Cantor Fitzgerald upgraded Omeros to Overweight and set a $22 target, increasing analyst support and attention; Omeros closed at $18.49 on Monday.
Follow Metlife Inc (MET) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for MET